Last reviewed · How we verify

NCT00415792

Administration of Human Chorionic Gonadotropin (hCG) Versus Gonadotropin Releasing Hormone (GnRH) Agonist for Ovulation Induction in Hyper-Responder Patients

Status unknown Phase 4 Last updated 4 January 2007
What this trial tests

Phase 4 trial testing Arvekap, Pregnyl in Infertility in 60 participants. Status unknown.

Timeline
1 November 2003
1 July 2005

Quick facts

Lead sponsorEugonia
PhasePhase 4
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment60
Start date1 November 2003
Estimated completion1 July 2005
Sites1 location across Greece

Drugs / interventions tested

Conditions studied

Sponsor

Eugonia — full company profile →

Who can join

Adults 18 to 50, female only, with Infertility. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

hCG and GnRH agonist can be used to induce final oocyte maturation and ovulation in IVF cycles. These two approaches will be compared in this study in terms of pregnancy rates and embryological data using patients with hyper-response to IVF drugs.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Infertility

Currently open trials in the same condition.

Other Eugonia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00415792.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing